Chief Medical Officer, public biotechnology company developing cancer immunotherapies  

“The [QuartzBio] platform is a good investment. Think about the turnover. The platform allows continuity for programs, nothing is lost in transitions. Very valuable as central repository of data. When people leave companies – and they have been massaging the data – the data is basically lost – I have no idea where to find it.”